Background and aims Several clinical factors have an impact on prognosis in stage II
colorectal cancer (CRC), but as yet they are inadequate for risk assessment. The present …

Purpose: Improved prognostic stratification of patients with stage II and III colorectal cancer
is warranted for postoperative clinical decision making. This study was conducted to develop …

Aims Despite continual efforts to develop prognostic and predictive models of colorectal
cancer by using clinicopathological and genetic parameters, a clinical test that can …

Purpose This study aims to develop a robust gene expression classifier that can predict
disease relapse in patients with early-stage colorectal cancer (CRC). Patients and Methods …

Background. Approximately 20% of patients with stage II colorectal cancer will experience a
relapse. Current clinical-pathologic stratification factors do not allow clear identification of …

Colorectal cancer (CRC) patients frequently experience disease recurrence and distant
metastasis. This study aimed to identify prognostic indicators, including individual responses …

Introduction The traditional staging system is inadequate to identify those patients with stage
II colorectal cancer (CRC) at high risk of recurrence or with stage III CRC at low risk. A …

Background A large number of patients with stage II/III colorectal cancer (CRC) have a high
recurrence rate after radical resection. We aimed to develop a novel tool to stratify patients …

Purpose The Dukes' staging system is the gold standard for predicting colorectal cancer
prognosis; however, accurate classification of intermediate-stage cases is problematic. We …

ColoPrint® is an 18-gene expression signature designed to predict disease relapse in
patients with early-stage colorectal cancer (CRC). We discuss the potential impact of …